ROS1 and neoplasm: When excluding 45 patients (15 male, 30 female) with activating EGFR mutations or ALK, ROS1, or RET gene fusions, this trend persisted in females, with median tumor class II IMM load of 103 in patients with at least 9 unique germline HLA-II alleles, as compared to 88 in patients with a higher degree of germline HLA homozygosity (MW p=0.06; Supplementary Figure 1).